These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 11393664)

  • 1. Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift.
    Epstein M
    J Hypertens; 2001 May; 19(5):829-42. PubMed ID: 11393664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aldosterone as a mediator of progressive renal dysfunction: evolving perspectives.
    Epstein M
    Intern Med; 2001 Jul; 40(7):573-83. PubMed ID: 11506295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications.
    Epstein M
    Am J Kidney Dis; 2001 Apr; 37(4):677-88. PubMed ID: 11273866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldosterone in progressive renal disease.
    Hostetter TH; Rosenberg ME; Ibrahim HN; Juknevicius I
    Semin Nephrol; 2001 Nov; 21(6):573-9. PubMed ID: 11709805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldosterone in renal disease.
    Hostetter TH; Rosenberg ME; Ibrahim HN; Juknevicius I
    Curr Opin Nephrol Hypertens; 2001 Jan; 10(1):105-10. PubMed ID: 11195042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease.
    Epstein M
    Am J Med; 2006 Nov; 119(11):912-9. PubMed ID: 17071154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of the renin-angiotensin-aldosterone system in the progression of renal disease: a critical review.
    Ibrahim HN; Rosenberg ME; Hostetter TH
    Semin Nephrol; 1997 Sep; 17(5):431-40. PubMed ID: 9316211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual blockade of aldosterone and angiotensin II additively suppresses TGF-beta and NADPH oxidase in the hypertensive kidney.
    Onozato ML; Tojo A; Kobayashi N; Goto A; Matsuoka H; Fujita T
    Nephrol Dial Transplant; 2007 May; 22(5):1314-22. PubMed ID: 17324946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldosterone in the development and progression of renal injury.
    Hollenberg NK
    Kidney Int; 2004 Jul; 66(1):1-9. PubMed ID: 15200407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypertension: renin-angiotensin-aldosterone system alterations.
    Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
    Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of the renin-angiotensin-aldosterone system for cerebrorenal protection.
    Lambers Heerspink HJ
    Contrib Nephrol; 2013; 179():7-14. PubMed ID: 23652444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic measures in proteinuric nephropathy.
    Praga M
    Kidney Int Suppl; 2005 Dec; (99):S137-41. PubMed ID: 16336567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldosterone is a major factor in the progression of renal disease.
    Ibrahim HN; Rosenberg ME; Greene EL; Kren S; Hostetter TH
    Kidney Int Suppl; 1997 Dec; 63():S115-9. PubMed ID: 9407437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes.
    Karalliedde J; Viberti G
    J Hum Hypertens; 2006 Apr; 20(4):239-53. PubMed ID: 16452996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinical approach in regression of glomerulosclerosis.
    Stoian M; Radulian G; Chiţac D; Simion E; Stoica V
    Rom J Intern Med; 2007; 45(2):215-8. PubMed ID: 18333378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of intrarenal angiotensin system activation, oxidative stress, inflammation, and impaired nuclear factor-erythroid-2-related factor 2 activity in the progression of focal glomerulosclerosis.
    Kim HJ; Sato T; Rodríguez-Iturbe B; Vaziri ND
    J Pharmacol Exp Ther; 2011 Jun; 337(3):583-90. PubMed ID: 21357516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benazepril, an angiotensin-converting enzyme inhibitor, alleviates renal injury in spontaneously hypertensive rats by inhibiting advanced glycation end-product-mediated pathways.
    Liu XP; Pang YJ; Zhu WW; Zhao TT; Zheng M; Wang YB; Sun ZJ; Sun SJ
    Clin Exp Pharmacol Physiol; 2009 Mar; 36(3):287-96. PubMed ID: 19018797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage.
    Mennuni S; Rubattu S; Pierelli G; Tocci G; Fofi C; Volpe M
    J Hum Hypertens; 2014 Feb; 28(2):74-9. PubMed ID: 23803592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal responses to angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor in partially nephrectomized spontaneously hypertensive rats.
    Okada H; Suzuki H; Kanno Y; Ikenaga H; Saruta T
    J Cardiovasc Pharmacol; 1995 Oct; 26(4):564-9. PubMed ID: 8569216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.